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Fig. 1: Least square means of RV by categorical patient order 
(corrected for CTV original and centre). 
 
Conclusions: Central review significantly improved the uniformity of 
the CTV delineation in the first ten rectal cancer patients submitted 
per centre. The high agreement on CTV delineations from the 
beginning of the review period and the fact that some centres 
submitted a low number of cases may explain the lack of a learning 
curve over the whole period. Further analysis of the data can highlight 
current ambiguities in the delineation guidelines and can help us in 
further improving these. 
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Purpose/Objective: Research on quality of cancer care (QoCC) during 
the last decade has demonstrated that the increase in knowledge on 
treatments with proven efficacy does not directly translate into 
optimal treatment delivery to patients. On the other hand, data 
describing the proportion of patients with rectal cancer (RC) who 
benefit of up-to-date evidence-based diagnostic-treatment procedures 
are still scarce in the literature. Aims of the present study are: 1) to 
describe the methods used for the selection of RC specific quality 
indicators (QI); 2) to analyse three QI concerning patients diagnosed 
with a new RC in Southern Switzerland and receiving neo-adjuvant 
radiation therapy (RT). 
Materials and Methods: QI have been developed in the context of a 
QoCC project as follows: seek and nomination of multidisciplinary RC 
Working Group, selection of QI on an evidence-based manner, choice 
of QI through a two-rounds Delphi-process and validation of final QI by 
an international Advisory Board (consensus ≥ 70%). Patients with RC 
incident from 2011 to 2012 were retrieved from the files of Ticino 
Cancer Registry. According to ICD-O-III tumour classification, 
epithelial tumours were included, but neuroendocrine, GIST, sarcoma, 
lymphoma. Additional information was extracted from the single 
pathology and RT records in both public and private hospitals. QI will 
be presented as proportion with the corresponding 95% confident 
intervals. The numerator and the denominator will be defined 
according to the definition of each QI. 
Results: We initially considered 51 rectum-specific QI, of which 15 
were RT-related. At the end of the whole process, 21 QI were finally 
validated (RT-related, N=9). Results of patients diagnosed with RC in 
2011-2012 will be presented for the following 3 RT-related QI: 1) 
proportion of patients with RC for which the request for the 
pathological examination includes the information of neo-adjuvant 
RT (in patients with RC undergoing neo-adjuvant RT and surgery); 2) 
proportion of patients with locally advanced RC undergoing neo-
adjuvant RT (in patients with locally advanced RC undergoing surgery; 
3) proportion of patients with RC and undergoing neo-adjuvant RT 
operated within 6-8 weeks after the end of neo-adjuvant RT (in 
patients with RC undergoing neo-adjuvant RT and surgery).  
Conclusions: QI are mandatory not only for clinicians, but also for 
stakeholders and patients. QI should be defined, developed and tested 
with scientific evidence-based rigor in a careful and transparent 
manner. The present QI study is based on expertise and active 
involvement of local health care providers and international experts 
representing all major disciplines (epidemiology, pathology, radiology, 
gastroenterology, surgery, radiation oncology, oncology, nuclear 
medicine), thus increasing quality, acceptance and translation of 
results into the daily clinical practice. 
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Purpose/Objective: To tailor treatment for locally advanced rectal 
cancer (LARC) an early accurate prediction of tumor response after 
preoperative chemoradiotherapy (CRT) is required. In literature, 
response prediction for LARC is mainly based on PET-imaging, but 
these studies are small and rarely validated. This study provides a 
prediction model based on a multicentric analysis of LARC response 
with clinical and sequential PET data of before and during treatment 
from three different institutes.  
Materials and Methods: In total, 112 patients from one institute were 
used to train the prediction model.The model was tested on 
respectively 78 and 28 patients from two different institutes. All LARC 
patients were prospectively accrued between 2007 and 2011 and 
received long-course radiotherapy (45-55 Gy) and concomitant 
chemotherapy. Two PETCT scans were made, pretreatment (day0) and 
halfway treatment (day 15). Tumors were semi-automatically 
contoured using a signal-to-background based threshold method. 
Extracted PET features of the two time points were SUVmean, SUVmax, 
metablic tumor volume (MTV) and maximal tumor diameter. Response 
indices between day0 and day 15 were calculated. They were 
analyzed together with age and gender of the patient and cT- and cN-
stage. The endpoint for prediction was pathologic complete response 
(pCR) defined as ypT0N0, based on pathology reviews of the resected 
specimen. Eleven patients who were also included in a wait-and-see 
study were considered to have pCR when they were recurrence free 
for at least 1 year. Significant predictors from a univariate Mann–
Whitney U test were included in a multivariate model based on 
logistic regression to predict tumor response. Performance of the 
model was expressed as a bootstrapped AUC (Area Under the Curve) of 
the Receiver Operating Characteristic (ROC).  
Results: The data distributions, number of missing values and pCR 
rates were similar between the institutes (Table). Based on the 
univariate analysis and outcome of the logistic regression, cT- and cN-
stage, maximal diameter at day15 and response index of SUVmax were 
selected as predictors. A nomogram was deducted from this model 
(Figure), resulting in performances of 0.78 for the training dataset and 
0.69 and 0.64 for the smaller validation datasets.  
 
 Conclusions: Sequential PET-imaging has predictive power for 
response after chemoradiotherapy in LARC patients. Application of the 
developed model in other institutes is less accurate, but still useful 
for tailored decision making. When patients are assigned to risk groups 
for an uncomplete response, high risk patients may be candidates for 
radiotherapy boost and adjuvant chemotherapy strategies, while the 
low risk patients may be followed-up with a wait-and-see policy, 
